All In Biotech

Drug Trial Radar · NCT05186753

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of The Safety and Efficacy of CGT9486 in Subjects With Nonadvanced Systemic Mastocytosis

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 237 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

237

Planned (sponsor's estimate)

Start

Jun 27, 2022

Primary completion

May 22, 2025

Study completion Jan 2030

Sponsor

Lead sponsor
Cogent Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jan 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdvSM), including indolent systemic mastocytosis and smoldering systemic mastocytosis, whose symptoms are not adequately controlled by BSC. This study will be conducted in three parts. Patients in Parts 1a, 1b and 2 will receive bezuclastinib or placebo, and may roll over onto Part 3 to receive treatment with bezuclastinib. Additionally, a substudy of subjects will investigate the efficacy, safety, and tolerability of bezuclastinib in patients who are experiencing inadequate symptom control with avapritinib.

Conditions

  • SSM
  • Mastocytosis, Indolent
  • Mastocytosis, Systemic
  • Mastocytosis
  • ISM
  • BMM
  • Smoldering Systemic Mastocytosis
  • Bone Marrow Mastocytosis

Interventions

  • Bezuclastinib Tablets (Formulation A)Drug

    Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

  • Bezuclastinib Tablets (Formulation B)Drug

    Bezuclastinib will be administered orally, once daily continuously for 28-day cycles

  • Placebo TabletsDrug

    Placebo will be administered orally, once daily continuously for 28-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Determine recommended dose of bezuclastinib (CGT9486) in subjects with NonAdvSMTime frame: 3 months
  2. Part 2: Efficacy of bezuclastinib at the selected dose versus placeboTime frame: 24 Weeks
  3. Part 3: Safety and tolerability of bezuclastinib as assessed by number of adverse eventsTime frame: Up to 5 years

Locations

57 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • One of a Kind Clinical Research Center

    Scottsdale, Arizona

  • Modena Allergy and Asthma Clinical

    La Jolla, California

  • Innovative Research of West Florida

    Clearwater, Florida

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • University of South Florida

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Rush University

    Chicago, Illinois

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Allervie Clinical Research

    Glenn Dale, Maryland

  • Institute for Asthma and Allergy

    Wheaton, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University at St. Louis

    St Louis, Missouri

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Duke University

    Raleigh, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • AIR Care

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Metrodora Institute of Technology

    West Valley City, Utah

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Antwerp University Hospital (UZA)

    Edegem, Belgium

  • CHU Tivoli

    La Louvière, Belgium

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • University of Alberta

    Edmonton, Alberta, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia

  • AP-HP- Hopital Pitie-Salpetriere

    Paris, France

  • CHU de Toulouse - Hopital Larrey

    Toulouse, France

  • Universitaetsklinikum Aachen, AoeR

    Aachen, Germany

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitätsklinikum Schleswig-Holstein

    Kiel, Germany

  • University Medical Centre Mannheim

    Mannheim, Germany

  • Cork University Hospital

    Cork, Ireland

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.